Lewes, DE -- (SBWire) -- 10/11/2013 --LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community. Out Today’s Focus is on: Cree, Inc. (NASDAQ:CREE), Tripadvisor Inc (NASDAQ:TRIP),NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Pharmacyclics, Inc. (NASDAQ:PCYC).

Cree, Inc. (NASDAQ:CREE), increased4.45% and closed at $72.09 on a traded volume of 2.38 million shares, in comparison to 2.42 million shares of average trading volume. So far this year, the stock is up over 112.15%.

The company has a total market capitalization of $8.66million and its total outstanding shares are 120.11 million.

Will CREE Continue To Move Higher? Find Out Here

Cree, Inc. develops, manufactures, and sells lighting-class light emitting diode (LED), lighting, and semiconductor products for power and radio-frequency (RF) applications in the United States, China, Europe, South Korea, Japan, Malaysia, and Taiwan.

Tripadvisor Inc (NASDAQ:TRIP),soared2.26% and closed at $72.27 on a traded volume of 2.37 million shares, whereas its average trading volume is 1.53 million shares. In the last three months, the stock is up16.7%. The Intra-day range for the stock is $70.15 and $72.80.

For How Long TRIP’s Gloss will Attract Investors? Find out via this report

TripAdvisor, Inc., an online travel company, enables travelers to plan and have the perfect trip. It offers advice from real travelers and various travel choices and planning features with seamless links to booking tools.

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) after opening its shares at the price of $31.61, jumped up7.78% to close the day at $33.15. The stock ended on a traded volume of 2.32 million shares, in comparison to 1.89 million shares of average trading volume. The 52-week range for the stock is $7.35 and $35.72 and during the previous trading session the stock scored the highest price of $33.35. It started the day at $31.61.

Why Should Investors Buy NPSP After The Recent Gain? Just Go Here and Find Out.

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States.

Pharmacyclics, Inc. (NASDAQ:PCYC), jumped up2.16 % and closed at $123.14. So far in three months, the stock is up 22.82%. The 52-week range for the stock is $44.91 and $143.34 and during the previous trading session it marked$124.75 as its highest price. The stock initially exchanged hands with a price of $124.55 and the overall traded volume that day was 2.29 million shares.

Will PCYC Continue To Move Higher? Find Out Here

Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases.

About LeadingStockAlerts
LeadingStockAlerts is a financial marketing firm that specializes in assisting the underserved small cap and micro-cap stock community.

Our site has been the clear choice for today’s investors and day-traders. As one of the internet’s premiere financial destinations, we offer the investment community some of the market’s leading emerging opportunities. Using a balanced combination of industry experience and high-tech offerings, this site keeps you ahead of the curve and ahead of the bell.

Disclaimer:
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT OR WEBSITE. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice.

The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

Read Full Disclaimer at: http://leadingstockalerts.com/disclaimer/